- Title
- European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
- Creator
- Lee, G. A.; Aktaa, S.; Jurczak, W.; Lopez, P. Garrido; Sverdlov, A. L.; Tocchetti, C. G.; Barac, A.; Parrini, I.; Zamorano, P.; Iakobishvili, Z.; Pudil, R.; Badimon, L.; Baker, E.; Kirby, A. M.; Blaes, AH; Farmakis, D; Curigliano, G; Stephens, R; Lyon, AR; Lopez-Fernandez, T; Gale, C. P.; Yaseen, Israa F.; Gulati, G.; Asteggiano, R.; Szmit, S.; Cohen-Solal, A.; Abdin, A.
- Relation
- European Heart Journal - Quality of Care and Clinical Outcomes Vol. 9, Issue 1, p. 1-7
- Publisher Link
- http://dx.doi.org/10.1093/ehjqcco/qcac070
- Publisher
- Oxford University Press
- Resource Type
- journal article
- Date
- 2023
- Description
- Aims: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
- Subject
- quality indicators; cardio-oncology; assessment; treatment; cancer therapy-related cardiovascular toxicity; outcomes; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1488254
- Identifier
- uon:52387
- Identifier
- ISSN:2058-5225
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 5144
- Visitors: 5043
- Downloads: 0
Thumbnail | File | Description | Size | Format |
---|